Oracea (Doxycycline)

Doxycycline, the active ingredient in Oracea, is a tetracycline antibiotic presented as an oral formulation for oral use. It is indicated for the management of rosacea, helping to reduce inflammatory lesions and facial redness in adult patients and is marketed in the European Union for chronic facial erythema.

GNH USA supplies Oracea as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Oracea (doxycycline) is employed in dermatology to address rosacea, a chronic inflammatory condition of the facial skin characterized by persistent redness, papules and pustules.

Rosacea: reduces inflammatory papules, pustules and persistent facial erythema, improving skin appearance in affected adults.

Oracea may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: mild stomach upset. - Diarrhea: loose stools. - Photosensitivity: increased skin sensitivity to sunlight. - Dry mouth: reduced salivation.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis): swelling, difficulty breathing. - Stevens‑Johnson syndrome or toxic epidermal necrolysis: severe skin blistering. - Hepatotoxicity: elevated liver enzymes or jaundice.

Before initiating therapy, several safety considerations should be reviewed. - Pregnancy: use only if clearly needed after risk‑benefit assessment. - Breastfeeding: may be excreted in milk; consult a healthcare professional. - Renal impairment: dose adjustment may be required; monitor renal function. - Sun exposure: avoid prolonged UV exposure; use sunscreen and protective clothing. - Drug interactions: review concomitant medications for potential interactions. - Store at room temperature: keep in original container, protect from moisture and heat.

Doxycycline can interact with several medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Antacids containing aluminum, magnesium or calcium: markedly reduce doxycycline absorption. - Isotretinoin: combined use increases risk of intracranial hypertension. - Warfarin: doxycycline may potentiate anticoagulant effect, increasing bleeding risk.

Moderate Interactions (Monitor Closely): - Oral contraceptives: efficacy may be decreased; consider alternative contraception. - Barbiturates and carbamazepine: may lower doxycycline plasma levels. - Methotrexate: concurrent use can increase methotrexate toxicity.